Cell & Gene The Podcast: Inside BlueRock Therapeutics’ Parkinson’s Disease Trial

Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company’s phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells’ (iPSCs) play in the trial, and they also discuss the company’s investigational cell therapy, bemdaneprocel.

Click here to listen.

Related News

Press Releases

BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel

May 30, 2024
Press Releases

BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months

March 6, 2024
Podcasts

Headlines of the Future Podcast: The Future of Cell and Gene Therapies

November 22, 2023
Press Releases

BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel

May 30, 2024
Press Releases

BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months

March 6, 2024
Podcasts

Headlines of the Future Podcast: The Future of Cell and Gene Therapies

November 22, 2023